<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: carefully", fill: "#893f45"},
{source: "1: carefully", target: "1: following factors", fill: "#893f45"},
{source: "1: following factors", target: "1: operations", fill: "#893f45"},
{source: "1: operations", target: "1: financial condition", fill: "#893f45"},
{source: "1: carefully", target: "4: Changes ", fill: "#b39eb5"},
{source: "4: Changes ", target: "4: pharmaceutical", fill: "#b39eb5"},
{source: "4: pharmaceutical", target: "4: biotechnology", fill: "#b39eb5"},
{source: "4: biotechnology", target: "4: industries", fill: "#b39eb5"},
{source: "4: industries", target: "4: materially adversely affect", fill: "#b39eb5"},
{source: "4: materially adversely affect", target: "4: operations", fill: "#b39eb5"},
{source: "4: operations", target: "4: growth rate", fill: "#b39eb5"},
{source: "4: Changes ", target: "20: December ", fill: "#c33"},
{source: "20: December ", target: "20: representatives", fill: "#c33"},
{source: "20: December ", target: "START_HERE", fill: "#c33"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals">Janssen Pharmaceuticals</a></td>
      <td>Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson &amp; Johnson. It was founded in 1953 by Paul Janssen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacology">Pharmacology</a></td>
      <td>Pharmacology is a branch of medicine, biology and pharmaceutical sciences concerned with drug or medication action, where a drug may be defined as any artificial, natural, or endogenous (from within the body) molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism (sometimes the word pharmacon is used as a term to encompass these endogenous and exogenous bioactive species). More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reliance_Industries">Reliance Industries</a></td>
      <td>Reliance Industries Limited is an Indian multinational conglomerate company, headquartered in Mumbai. It has diverse businesses including energy, petrochemicals, natural gas, retail, telecommunications, mass media, and textiles.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Koch_Industries">Koch Industries</a></td>
      <td>Koch Industries, Inc. () is an American privately held multinational conglomerate corporation based in Wichita, Kansas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Goodwill_Industries">Goodwill Industries</a></td>
      <td>Goodwill Industries International Inc., often shortened in speech and writing to Goodwill (stylized as goodwill), is an American nonprofit 501(c)(3) organization that provides job training, employment placement services, and other community-based programs for people who have barriers to their employment. Goodwill Industries also hires veterans and individuals who lack either education, job experience or face employment challenges.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/PPG_Industries">PPG Industries</a></td>
      <td>PPG Industries, Inc. is an American Fortune 500 company and global supplier of paints, coatings, and specialty materials.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hindalco_Industries">Hindalco Industries</a></td>
      <td>Hindalco Industries Limited an Indian aluminium and copper manufacturing company, is a subsidiary of the Aditya Birla Group. Its headquarters are at Mumbai, Maharashtra, India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Britannia_Industries">Britannia Industries</a></td>
      <td>Britannia Industries Limited is an Indian company specialised in food industry, part of the Wadia Group headed by Nusli Wadia. Founded in 1892 and headquartered in Kolkata, it is one of India's oldest existing companies and best known for its biscuit products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_United_States_representatives_from_New_York">List of United States representatives from New York</a></td>
      <td>The following is a list of members of the United States House of Representatives from the state of New York. For chronological tables of members of both houses of the United States Congress from the state (through the present day), see United States congressional delegations from New York.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Representative_democracy">Representative democracy</a></td>
      <td>Representative democracy, also known as indirect democracy, is a type of democracy where elected persons represent a group of people, in contrast to direct democracy. Nearly all modern Western-style democracies function as some type of representative democracy: for example, the United Kingdom (a unitary parliamentary constitutional monarchy), India (a federal parliamentary republic), France (a unitary semi-presidential republic), and the United States (a federal presidential republic).Representative democracy can function as an element of both the parliamentary and the presidential systems of government.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/House_of_Representatives_of_the_Philippines">House of Representatives of the Philippines</a></td>
      <td>The House of Representatives of the Philippines (Filipino: Kapulungan ng mga Kinatawan ng Pilipinas) is the lower house of the Congress of the Philippines. Informally known as the Kamara (from the Spanish word Cámara, meaning "chamber"), the lower house is usually called Congress, although the term collectively refers to both houses.Members of the House are officially styled as representative (kinatawan) and sometimes informally called congressmen or congresswomen (mga kongresista) and are elected to a three-year term.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/House_of_Representatives_(Morocco)">House of Representatives (Morocco)</a></td>
      <td>The House of Representatives (Arabic: مجلس النواب [maʒ.li.s‿an.nu.waːb]; Berber languages: ⴰⵙⵇⵇⵉⵎ ⵏ ⵉⵎⵓⵔⴰ, romanized: Asqqim n Imura; French: Chambre des représentants) is one of the two chambers—the other of which is the House of Councillors—of the Moroccan Parliament. The House of Representatives has 395 members elected for five-year terms, 305 of whom are elected in multi-seat constituencies, and 90 of whom are elected in two national lists dedicated to promote gender equality and national youth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Results_of_the_2019_Australian_federal_election_(House_of_Representatives)">Results of the 2019 Australian federal election (House of Representatives)</a></td>
      <td>The state-by-state results in the Australian House of Representatives at the 2019 federal election are: Coalition 77, Labor 68, Australian Greens 1, Centre Alliance 1, Katter's Australian Party 1, and Independents 3.\n\n\n== Australia ==\n\n\n== States ==\n\n\n=== New South Wales ===\n\n\n=== Victoria ===\n\n\n=== Queensland ===\n\n\n=== Western Australia ===\n\n\n=== South Australia ===\n\n\n=== Tasmania ===\n\n\n== Territories ==\n\n\n=== Australian Capital Territory ===\n\n\n=== Northern Territory ===\n\n\n== References ==\n\n\n== External links ==\nAustralian Electoral Commission: 2019 Tally Room\nABC Elections: 2019 Federal Election Results\nHow did we vote?</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/1978_United_States_House_of_Representatives_elections">1978 United States House of Representatives elections</a></td>
      <td>The 1978 United States House of Representatives elections was an election for the United States House of Representatives in 1978 which occurred in the middle of Democratic President Jimmy Carter's term, amidst an energy crisis and rapid inflation. The Democratic Party lost a net of 15 seats to the Republican Party, and thus lost their two-thirds supermajority, but still maintained a large 277-seat majority.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PDI INC      ITEM 1A RISK FACTORS           In addition to the other information provided in this report, you should     <font color="blue">carefully</font>  consider  the <font color="blue">following factors</font> in evaluating our business,     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not     <font color="blue">presently known</font> to us, that we currently deem immaterial or that are similar     to those <font color="blue">faced by</font> other companies in our industry or business in general,     such as competitive conditions, may also impair our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The     occurrence of any of the <font color="blue">following risks could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in outsourcing trends in the <font color="blue">pharmaceutical</font> and <font color="blue">biotechnology</font>     <font color="blue">industries</font>  could  <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our business, financial     condition, results of <font color="blue">operations</font> and <font color="blue">growth rate</font></td>
    </tr>
    <tr>
      <td>Our  business  and  growth  depend  in  large  part <font color="blue">on demand from</font> the     <font color="blue">pharmaceutical</font> and life sciences <font color="blue">industries</font> for <font color="blue">outsourced marketing</font> and     <font color="blue">sales services</font></td>
    </tr>
    <tr>
      <td>The practice of many companies in these <font color="blue">industries</font> has been     to <font color="blue">hire outside organizations</font> like us to conduct large sales and marketing     projects</td>
    </tr>
    <tr>
      <td>However, <font color="blue">companies may elect</font> to perform these <font color="blue">services <font color="blue">internally</font></font>     for a variety of reasons, including the rate of <font color="blue">new product development</font> and     FDA approval of those products, number of <font color="blue">sales <font color="blue"><font color="blue">representative</font>s</font> employed</font>     <font color="blue">internally</font> in relation to demand for or the need to <font color="blue">promote new</font> and existing     products, and <font color="blue"><font color="blue">competition</font> from</font> other suppliers</td>
    </tr>
    <tr>
      <td>Recently, there has been a     slow-down in the rate of approval of <font color="blue">new products by</font> the FDA and this trend     may continue</td>
    </tr>
    <tr>
      <td>If the <font color="blue">pharmaceutical</font> and life sciences <font color="blue">industries</font> reduce     their  tendency  to  outsource these projects, our business, financial     condition,  results  of <font color="blue">operations</font> and <font color="blue">growth rate</font> could be <font color="blue">materially</font>     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>9       _________________________________________________________________                                     PDI, INC                     Annual Report on Form 10-K (Continued)       Our service <font color="blue">businesses</font> depend on <font color="blue">expenditures</font> by companies in the life     sciences <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">service revenue</font>s depend on promotional, marketing and <font color="blue">sales <font color="blue">expenditures</font></font>     by companies in the life sciences <font color="blue">industries</font>, including the <font color="blue">pharmaceutical</font>,     MD&amp;D  and  <font color="blue">biotechnology</font>  <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>Promotional, marketing and sales     <font color="blue">expenditures</font> by <font color="blue">pharmaceutical</font> manufacturers have in the past been, and     could  in  the  future be, negatively impacted by, among other things,     <font color="blue">governmental reform</font> or <font color="blue">private market initiatives intended</font> to reduce the     cost of <font color="blue">pharmaceutical</font> products or by governmental, medical association or     <font color="blue">pharmaceutical</font> industry initiatives designed to regulate the manner in which     <font color="blue">pharmaceutical</font> manufacturers promote their products</td>
    </tr>
    <tr>
      <td>Furthermore, the trend     in  the  life sciences <font color="blue">industries</font> toward <font color="blue">consolidation</font> may result in a     reduction in <font color="blue">overall sales</font> and <font color="blue">marketing <font color="blue">expenditures</font></font> and, <font color="blue">potentially</font>, a     reduction in the use of <font color="blue">contract sales</font> and <font color="blue">marketing services providers</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">service revenue</font> is derived from a limited number of clients, the     loss of any one of which could <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affect</font> our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our revenue and <font color="blue">profitability depend</font> to a great extent on our <font color="blue"><font color="blue">relationship</font>s</font>     with a limited number of large <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>In 2005, we had     <font color="blue">three major clients</font> that accounted for <font color="blue">approximately</font> 33dtta6prca, 21dtta7prca and 15dtta0prca,     <font color="blue">respectively</font>, or a total of <font color="blue">approximately</font> 70dtta3prca of our <font color="blue">service revenue</font></td>
    </tr>
    <tr>
      <td>In     2004, our <font color="blue">two major clients accounted</font> for a total of <font color="blue">approximately</font> 63dtta0prca of     our <font color="blue">service revenue</font></td>
    </tr>
    <tr>
      <td>We are likely to continue to experience a high degree     of client concentration, <font color="blue">particularly</font> if there is further <font color="blue">consolidation</font>     within the <font color="blue">pharmaceutical</font> industry</td>
    </tr>
    <tr>
      <td>The loss or a <font color="blue">significant reduction</font> of     business from any of our <font color="blue">major clients could</font> have a material adverse effect     on our business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For example,     in  <font color="blue">December </font>2004, we announced a reduction in the aggregate number of     <font color="blue"><font color="blue">representative</font>s</font> that we deployed for AstraZeneca</td>
    </tr>
    <tr>
      <td>This <font color="blue">reduction decreased</font>     <font color="blue">revenue generated from</font> <font color="blue">AstraZeneca </font>in 2005 by <font color="blue">approximately</font> dlra45dtta8 million     from revenues generated in 2004</td>
    </tr>
    <tr>
      <td>Further, as announced on <font color="blue">February </font>28, 2006,     <font color="blue">AstraZeneca </font>is <font color="blue">terminating</font> its <font color="blue">contract sales</font> force arrangement with us     <font color="blue">effective</font> April 30, 2006</td>
    </tr>
    <tr>
      <td>The <font color="blue">termination</font> affects <font color="blue">approximately</font> 800 field     <font color="blue"><font color="blue">representative</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">revenue impact</font> is projected to be <font color="blue">approximately</font> dlra65 to     dlra70 million in 2006</td>
    </tr>
    <tr>
      <td>Our <font color="blue">service contracts</font> are <font color="blue">generally</font> short-term <font color="blue">agreements</font> and are <font color="blue">cancelable</font>     at any time, which may result in <font color="blue">lost revenue</font> and <font color="blue"><font color="blue">additional</font> costs</font> and     expenses</td>
    </tr>
    <tr>
      <td>Our  service  contracts are <font color="blue">generally</font> for a term of one to <font color="blue">three years</font>     (certain of our operating entities have contracts of <font color="blue">shorter duration</font>) and     many  may  be  terminated  by  the  <font color="blue">client at</font> any time for any reason</td>
    </tr>
    <tr>
      <td>Additionally, certain of our clients have the ability to <font color="blue">significantly</font>     reduce the number of <font color="blue"><font color="blue">representative</font>s</font> we <font color="blue">deploy on</font> their behalf</td>
    </tr>
    <tr>
      <td>For example,     as  discussed  above,  as  a  result of the reduction in the number of     <font color="blue"><font color="blue">representative</font>s</font> we deployed for AstraZeneca, we generated <font color="blue">approximately</font>     dlra45dtta8 million less revenue from our <font color="blue">AstraZeneca </font><font color="blue">relationship</font> in 2005 than we     realized in 2004</td>
    </tr>
    <tr>
      <td>Further, as announced on <font color="blue">February </font>28, 2006, <font color="blue">AstraZeneca </font>is     <font color="blue">terminating</font> its <font color="blue">contract sales</font> force arrangement with us <font color="blue">effective</font> April 30,     2006</td>
    </tr>
    <tr>
      <td>The     <font color="blue">revenue impact</font> is projected to be <font color="blue">approximately</font> dlra65 to dlra70 million in 2006</td>
    </tr>
    <tr>
      <td>The <font color="blue">termination</font> or <font color="blue">significant reduction</font> of a <font color="blue">contract by one</font> of our major     clients not only results in <font color="blue">lost revenue</font>, but also typically causes us to     incur <font color="blue"><font color="blue">additional</font> costs</font> and expenses</td>
    </tr>
    <tr>
      <td>All of our sales <font color="blue"><font color="blue">representative</font>s</font> are     employees rather than <font color="blue">independent</font> <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>Accordingly, when a contract     is <font color="blue">significantly</font> reduced or terminated, unless we can <font color="blue">immediately transfer</font>     the related <font color="blue">sales force</font> to a new program, if <font color="blue">permitted under</font> the contract,     we <font color="blue">must either continue</font> to compensate those employees, without realizing any     related  revenue, or terminate their <font color="blue">employment</font></td>
    </tr>
    <tr>
      <td>If we terminate their     <font color="blue">employment</font>, we <font color="blue">may <font color="blue">incur significant expense</font>s</font> relating to their <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>The loss, <font color="blue">termination</font> or <font color="blue">significant reduction</font> of a large contract or the     loss of <font color="blue">multiple contracts could</font> have a material adverse effect on our     business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>We could face substantial product <font color="blue">liability</font> claims in the event any of the     <font color="blue">pharmaceutical</font> or medical device products we market now or in the future are     alleged to cause <font color="blue">negative reactions</font> or adverse side effects or in the event     any of these products causes injury, is alleged to be unsuitable for its     <font color="blue">intended purpose</font> or is alleged to be otherwise defective</td>
    </tr>
    <tr>
      <td>For example, we     have  been  named in <font color="blue">numerous lawsuits as</font> a result of our detailing of     Baycolâ on behalf of Bayer Corporation (Bayer)</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims,     <font color="blue">regardless</font>  of  their  merits, could be costly and divert <font color="blue">management</font>apstas     attention,  or  <font color="blue">adversely</font> affect our reputation and the demand for our     services or products</td>
    </tr>
    <tr>
      <td>We rely on contractual <font color="blue">indemnification provisions</font> with     our clients to protect us against certain product <font color="blue">liability</font> related claims</td>
    </tr>
    <tr>
      <td>There is no assurance that these <font color="blue">provisions will</font> be <font color="blue">fully enforceable</font> or     that they <font color="blue">will provide adequate protection against</font> claims intended to be     covered</td>
    </tr>
    <tr>
      <td>We currently have product <font color="blue">liability</font> insurance in the aggregate     amount of dlra5dtta0 million but we <font color="blue">cannot assure</font> that our <font color="blue">insurance will</font> be     sufficient to <font color="blue">cover fully</font> all potential claims for which the <font color="blue">aforementioned</font>     <font color="blue">indemnification provisions</font> do not <font color="blue">protect against</font></td>
    </tr>
    <tr>
      <td>Also, <font color="blue">adequate insurance</font>     <font color="blue">coverage might</font> not be available in the future at acceptable costs, if at     all</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________                                     PDI, INC                     Annual Report on Form 10-K (Continued)       If we do not <font color="blue">meet performance goals set</font> in our incentive-based and revenue     <font color="blue">sharing <font color="blue">arrangements</font></font>, our <font color="blue">profits could suffer</font></td>
    </tr>
    <tr>
      <td>We sometimes <font color="blue">enter into</font> incentive-based and revenue <font color="blue">sharing <font color="blue">arrangements</font></font>     with <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>Under incentive-based <font color="blue">arrangements</font>, we are     <font color="blue">typically paid</font> a fixed fee and, in addition, have an <font color="blue">opportunity</font> to increase     our <font color="blue">earnings <font color="blue">based on</font></font> the <font color="blue">market performance</font> of the products being detailed     in relation to targeted sales volumes, <font color="blue">sales force</font> performance metrics or a     <font color="blue">combination thereof</font></td>
    </tr>
    <tr>
      <td>Additionally, certain of our <font color="blue">service contracts</font> may     <font color="blue">contain penalty provisions pursuant</font> to which our fees may be <font color="blue">significantly</font>     reduced if we do not <font color="blue">meet certain performance metrics</font>, for example number     and timing of sales calls, physician reach, territory vacancies and/or sales     <font color="blue">representative</font>  turnover</td>
    </tr>
    <tr>
      <td>Under  revenue  sharing  <font color="blue">arrangements</font>,  our     <font color="blue">compensation</font>  is <font color="blue">based on</font> the <font color="blue">market performance</font> of the products being     detailed, usually expressed as a percentage of <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>These types of     <font color="blue">arrangements</font> transfer some <font color="blue">market risk from</font> our clients to us</td>
    </tr>
    <tr>
      <td>In addition,     these <font color="blue">arrangements</font> can result in <font color="blue">variability</font> in revenue and <font color="blue">earnings due</font> to     <font color="blue">seasonality</font>  of  product  usage,  changes in market share, new product     introductions, overall promotional efforts and other market related factors</td>
    </tr>
    <tr>
      <td>If we pursue a strategy that includes <font color="blue">copromotion</font> and <font color="blue">exclusive <font color="blue">distribution</font></font>     <font color="blue">arrangements</font>, and/or licensing and brand ownership of products, we cannot     assure you that we can <font color="blue">successfully</font> develop this business</td>
    </tr>
    <tr>
      <td>We  may  in  the  <font color="blue">future pursue</font> a <font color="blue">strategy which</font> includes <font color="blue">copromotion</font>,     <font color="blue">distribution</font> <font color="blue">arrangements</font>, and/or licensing and brand ownership of products</td>
    </tr>
    <tr>
      <td>These  types  of <font color="blue">arrangements</font> can <font color="blue">significantly</font> increase our operating     <font color="blue">expenditures</font>  in  the  short-term</td>
    </tr>
    <tr>
      <td>Typically, these <font color="blue">agreements</font> require     significant “upfront” payments, minimum purchase <font color="blue">requirements</font>, minimum     royalty  payments, payments to <font color="blue">third parties</font> for production, inventory     maintenance and control, <font color="blue">distribution</font> services and <font color="blue">accounts receivable</font>     administration, as well as sales and <font color="blue">marketing <font color="blue">expenditures</font></font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">particularly</font> where we license or acquire products before they are approved     for <font color="blue">commercial use</font>, we may be required to <font color="blue">incur significant expense</font> to gain     and maintain the required <font color="blue"><font color="blue">regulatory approval</font>s</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">regulatory approval</font>     does not <font color="blue">ensure commercial success</font></td>
    </tr>
    <tr>
      <td>As a result, our working capital balance     and cash flow position could be <font color="blue">materially</font> and <font color="blue">adversely</font> affected until the     products in question become <font color="blue">commercially</font> viable, if ever</td>
    </tr>
    <tr>
      <td>The risks that we     face in developing this segment of our business, if we choose to pursue it,     may increase in <font color="blue">proportion with</font>:           ·       the number and types of <font color="blue">products covered by</font> these types of <font color="blue">agreements</font>;       ·       the <font color="blue">applicable stage</font> of the <font color="blue">drug regulatory process</font> of the <font color="blue">products at</font> the     time we <font color="blue">enter into</font> these <font color="blue">agreements</font>;       ·       the incidence of <font color="blue">adverse patent</font> and other <font color="blue">intellectual property developments</font>     relating to our <font color="blue">product portfolio</font>; and       ·       our <font color="blue">control over</font> the manufacturing, <font color="blue">distribution</font> and <font color="blue">marketing processes</font></td>
    </tr>
    <tr>
      <td>In the event that we pursue a <font color="blue">strategy which</font> includes the <font color="blue">copromotion</font>,     <font color="blue">distribution</font>, and/or licensing and brand ownership of products, there is no     assurance that we will be able to <font color="blue">successfully</font> implement this strategy</td>
    </tr>
    <tr>
      <td>We may make <font color="blue"><font color="blue">acquisition</font>s</font> in the <font color="blue">future which may lead</font> to <font color="blue">disruptions</font> to our     ongoing business</td>
    </tr>
    <tr>
      <td>Historically, we have made a number of <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue">will continue</font> to     <font color="blue">review new <font color="blue">acquisition</font> <font color="blue">opportunities</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font>     integrate an acquired company, the <font color="blue"><font color="blue">acquisition</font> could lead</font> to <font color="blue">disruptions</font> to     our business</td>
    </tr>
    <tr>
      <td>The success of an <font color="blue">acquisition</font> will depend upon, among other     things, our ability to:           ·       assimilate the <font color="blue">operations</font> and services or products of the acquired company;       ·       <font color="blue">integrate new personnel due</font> to the <font color="blue">acquisition</font>;       ·       retain and <font color="blue">motivate key employees</font>;       ·       retain customers; and       ·       minimize  the  diversion of <font color="blue">management</font>’s <font color="blue">attention from</font> other business     concerns</td>
    </tr>
    <tr>
      <td>In the event that the <font color="blue">operations</font> of an acquired business do not meet our     <font color="blue">performance expectations</font>, we may have to <font color="blue">restructure</font> the acquired business     or  write-off  the  value of some or all of the assets of the acquired     business, including goodwill and other <font color="blue">intangible assets</font> identified at time     of  <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>For example, during 2005, we <font color="blue">wrote down goodwill</font> and     <font color="blue">intangible assets</font> associated with our MD&amp;D business unit in the amount of     dlra8dtta2 million and goodwill for our <font color="blue">Select Access </font>business unit in the amount     of dlra3dtta3 million, both of which were acquired <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________                                     PDI, INC                     Annual Report on Form 10-K (Continued)       We, a current officer, and a <font color="blue">former officer</font> are <font color="blue">defendants</font> in a class action     <font color="blue">shareholder lawsuit which could divert</font> our time and <font color="blue">attention from</font> more     <font color="blue">productive <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Beginning </font>on January 24, 2002, several purported class <font color="blue">action complaints</font>     were  filed in the US District Court for the District of New Jersey,     <font color="blue">against us</font> and certain of our <font color="blue">officers on behalf</font> of persons who purchased     our <font color="blue"><font color="blue">common stock</font> during</font> the <font color="blue">period between</font> May 22, 2001 and August 12, 2002</td>
    </tr>
    <tr>
      <td>On May 23, 2002 the court <font color="blue">consolidated</font> these suits into a single class     <font color="blue">action lawsuit</font> and on August 22, 2005, in response to our motion, the court     dismissed the <font color="blue">complaint without prejudice</font></td>
    </tr>
    <tr>
      <td>On October 21, 2005, the lead     <font color="blue">plaintiff filed</font> a <font color="blue">third <font color="blue">consolidated</font></font> and <font color="blue">amended complaint</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>21,     2005,  we filed a motion to dismiss the <font color="blue">third amended</font> and <font color="blue">consolidated</font>     complaint</td>
    </tr>
    <tr>
      <td>On <font color="blue">February </font>24, 2006, the lead <font color="blue">plaintiff filed</font> a <font color="blue">memorandum</font> of     law in opposition to our motion to dismiss</td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">meritorious</font>     defenses exist to the <font color="blue">allegations</font> asserted in this lawsuit and we intend to     <font color="blue">vigorously defend</font> this action</td>
    </tr>
    <tr>
      <td>Although we currently maintain director and     officer <font color="blue">liability</font> <font color="blue">insurance coverage</font>, there is no assurance that we will     continue  to  maintain <font color="blue">such coverage</font> or that any <font color="blue">such coverage</font> will be     adequate to <font color="blue">offset potential damages</font></td>
    </tr>
    <tr>
      <td>Our failure, or that of our clients, to <font color="blue"><font color="blue">comply with</font> applicable healthcare</font>     <font color="blue">regulations</font> could limit, prohibit or otherwise <font color="blue">adversely</font> impact our business     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Various laws, <font color="blue">regulations</font> and <font color="blue">guidelines</font> established by government, industry     and professional bodies affect, among other matters, the provision of,     licensing,  labeling,  marketing,  promotion, sale and <font color="blue">distribution</font> of     <font color="blue">healthcare services</font> and products, including <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>In     particular, the <font color="blue">healthcare industry</font> is <font color="blue">governed by various federal</font> and state     <font color="blue">laws pertaining</font> to <font color="blue">healthcare fraud</font> and abuse, including <font color="blue">prohibitions on</font> the     payment or <font color="blue">acceptance</font> of kickbacks or other <font color="blue">remuneration</font> in return for the     purchase or lease of products that are paid for by <font color="blue">Medicare or Medicaid</font></td>
    </tr>
    <tr>
      <td><font color="blue">Sanctions </font>for violating these laws include civil and criminal fines and     penalties and possible exclusion from Medicare, Medicaid and other federal     or state <font color="blue">healthcare programs</font></td>
    </tr>
    <tr>
      <td>Although we believe our current business     <font color="blue">arrangements</font> do not violate these federal and state fraud and <font color="blue">abuse laws</font>, we     cannot be certain that our business <font color="blue">practices will</font> not be <font color="blue">challenged under</font>     these laws in the future or that a <font color="blue">challenge would</font> not have a material     adverse  effect  on  our  business,  <font color="blue">financial condition</font> or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our failure, or the failure of our clients, to <font color="blue">comply with</font> these     laws, <font color="blue">regulations</font> and <font color="blue">guidelines</font>, or any change in these laws, <font color="blue">regulations</font>     and <font color="blue">guidelines</font> may, among other things, limit or prohibit our business     <font color="blue">activities</font> or those of our clients, subject us or our clients to adverse     publicity, increase the cost of <font color="blue">regulatory compliance</font> and <font color="blue">insurance coverage</font>     or subject us or our clients to <font color="blue">monetary fines</font> or other penalties</td>
    </tr>
    <tr>
      <td>Our industry is <font color="blue">highly competitive</font> and our failure to <font color="blue">address competitive</font>     <font color="blue">developments promptly will limit</font> our ability to retain and increase our     market share</td>
    </tr>
    <tr>
      <td>Our <font color="blue">primary <font color="blue">competitors</font></font> for sales and marketing services include in-house     sales and <font color="blue">marketing departments</font> of <font color="blue">pharmaceutical</font> companies, other CSOs and     medical <font color="blue">education</font> and marketing research providers</td>
    </tr>
    <tr>
      <td>There are <font color="blue">relatively few</font>     barriers to entry in the <font color="blue">businesses</font> in which we compete and, as the industry     continues to evolve, new <font color="blue">competitors</font> are likely to emerge</td>
    </tr>
    <tr>
      <td>Many of our     current  and  potential  <font color="blue">competitors</font>  are  larger than we are and have     <font color="blue">substantially</font> greater capital, personnel and other <font color="blue">resources than</font> we have</td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font><font color="blue"><font color="blue">competition</font> may lead</font> to <font color="blue">competitive practices</font> that could have a     material adverse effect on our market share, our ability to <font color="blue">source new</font>     business <font color="blue">opportunities</font>, our business, <font color="blue">financial condition</font> or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our stock price is volatile and could be <font color="blue">further affected by events</font> not     within our control</td>
    </tr>
    <tr>
      <td>In 2005, our <font color="blue">stock traded at</font> a low of dlra11dtta12 and a high     of  dlra22dtta26</td>
    </tr>
    <tr>
      <td>In 2004, our <font color="blue">stock traded at</font> a low of dlra18dtta84 and a high of     dlra33dtta23</td>
    </tr>
    <tr>
      <td>The market for our <font color="blue">common stock</font> is volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our common     stock has been and <font color="blue">will continue</font> to be subject to:           ·       <font color="blue">volatility</font> in the trading markets <font color="blue">generally</font>;       ·       <font color="blue">significant fluctuations</font> in our quarterly operating results;       ·       <font color="blue">announcements</font> regarding our business or the business of our <font color="blue">competitors</font>;       ·       industry and/or <font color="blue">regulatory developments</font>;       ·       changes in revenue mix;       ·       changes in revenue and revenue <font color="blue">growth rate</font>s for us and for our <font color="blue">industry as</font> a     whole; and       ·       statements or changes in opinions, ratings or earnings estimates made by     <font color="blue">brokerage firms</font> or <font color="blue">industry analysts</font> relating to the markets in which we     operate or expect to operate</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________                                     PDI, INC                     Annual Report on Form 10-K (Continued)           Our <font color="blue">quarterly revenues</font> and operating results may vary, which may cause the     price of our <font color="blue">common stock</font> to fluctuate</td>
    </tr>
    <tr>
      <td>Our quarterly operating results <font color="blue">may vary as</font> a result of a number of factors,     including:           ·       commencement, delay, cancellation or <font color="blue">completion</font> of programs;       ·       <font color="blue">regulatory developments</font>;       ·       <font color="blue">uncertainty</font>  related  to  <font color="blue">compensation</font>  <font color="blue">based on</font> achieving performance     <font color="blue">benchmarks</font>;       ·       mix of <font color="blue">services provided</font> and /or mix of programs, ie, <font color="blue">contract sales</font>,     medical <font color="blue">education</font>, marketing research;       ·       timing and amount of expenses for <font color="blue">implementing new programs</font> and accuracy of     estimates of resources required for <font color="blue">ongoing programs</font>;       ·       timing and <font color="blue">integration</font> of <font color="blue"><font color="blue">acquisition</font>s</font>;       ·       changes in <font color="blue">regulations</font> related to <font color="blue">pharmaceutical</font> companies; and       ·       <font color="blue">general economic conditions</font></td>
    </tr>
    <tr>
      <td>In  addition,  in the case of revenue related to <font color="blue">service contracts</font>, we     recognize <font color="blue">revenue as services</font> are performed, <font color="blue">while program costs</font>, other than     <font color="blue">training costs</font>, are <font color="blue">expensed as incurred</font></td>
    </tr>
    <tr>
      <td>As a result, during the first two     to  three  months of a <font color="blue">new contract</font>, we may incur substantial expenses     associated  <font color="blue">with implementing</font> that <font color="blue">new program without</font> recognizing any     <font color="blue">revenue under</font> that contract</td>
    </tr>
    <tr>
      <td>This could have a material <font color="blue">adverse impact on</font>     our operating results and the price of our <font color="blue">common stock</font> for the quarters in     which these expenses are incurred</td>
    </tr>
    <tr>
      <td>For these and other reasons, we believe     that <font color="blue">quarterly comparisons</font> of our financial results are not <font color="blue">necessarily</font>     <font color="blue">meaningful</font>  and  should  not be <font color="blue">relied upon as</font> an <font color="blue">indication</font> of future     performance</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in quarterly results could <font color="blue">materially</font> <font color="blue">adversely</font>     affect the market price of our <font color="blue">common stock</font> in a <font color="blue">manner unrelated</font> to our     long-term operating performance</td>
    </tr>
    <tr>
      <td>We may require <font color="blue"><font color="blue">additional</font> funds</font> in order to implement our evolving business     model</td>
    </tr>
    <tr>
      <td>We  may  require  <font color="blue">additional</font>  funds  in order to pursue other business     <font color="blue">opportunities</font> or <font color="blue">meet future</font> operating <font color="blue">requirements</font>; develop <font color="blue">incremental</font>     marketing and sales capabilities; and/or acquire other services <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We may seek <font color="blue">additional</font> funding through public or <font color="blue">private equity</font> or debt     financing or other <font color="blue">arrangements</font> with collaborative partners</td>
    </tr>
    <tr>
      <td>If we raise     <font color="blue"><font color="blue">additional</font> funds</font> by issuing equity securities, further dilution to existing     <font color="blue"><font color="blue">stockholders</font> may</font> result</td>
    </tr>
    <tr>
      <td>In addition, as a condition to <font color="blue">providing us with</font>     <font color="blue"><font color="blue">additional</font> funds</font>, future investors may demand, and may be granted, rights     superior to those of <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>We cannot be sure, however, that     <font color="blue">additional</font> financing will be <font color="blue">available from</font> any of these sources or, if     available, will be <font color="blue">available on</font> acceptable or <font color="blue">affordable terms</font></td>
    </tr>
    <tr>
      <td>If adequate     <font color="blue"><font color="blue">additional</font> funds</font> are not available, we may be required to delay, reduce the     scope of, or <font color="blue">eliminate one</font> or more of our <font color="blue">growth strategies</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">attract key employees</font>, we may be unable to support the     growth of our business</td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font>execution of our business strategy depends, in large part, on our     ability to attract and retain qualified <font color="blue">management</font>, marketing and other     <font color="blue">personnel with</font> the skills and <font color="blue">qualifications necessary</font> to fully execute our     programs  and  strategy</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for talent among companies in the     <font color="blue">pharmaceutical</font> industry is intense and we <font color="blue">cannot assure</font> you that we will be     able to continue to attract or retain the <font color="blue">talent necessary</font> to support the     growth of our business</td>
    </tr>
    <tr>
      <td>Our business will suffer if we are unable to hire and retain <font color="blue">key <font color="blue">management</font></font>     personnel to <font color="blue">fill critical vacancies</font></td>
    </tr>
    <tr>
      <td>The success of our business <font color="blue">also <font color="blue">depends on</font></font> our ability to attract and     retain <font color="blue">qualified <font color="blue">senior <font color="blue">management</font></font></font>, and experienced <font color="blue">financial executives</font> who     are  in high demand and who often have competitive <font color="blue">employment</font> options</td>
    </tr>
    <tr>
      <td>Currently, we have <font color="blue">two significant vacancies</font> in our <font color="blue">senior <font color="blue">management</font></font></td>
    </tr>
    <tr>
      <td>Charles T Saldarini, our <font color="blue">former chief executive officer</font> and <font color="blue">vice chairman</font>     of our board of <font color="blue">directors</font> resigned <font color="blue">effective</font> October 21, 2005 and has been     <font color="blue">replaced as chief executive officer on</font> an <font color="blue">interim basis by</font> <font color="blue">Larry Ellberger</font></td>
    </tr>
    <tr>
      <td>Also,  in  August 2005, Bernard C Boyle, our <font color="blue">chief financial officer</font>,     announced his intention to retire <font color="blue">effective</font> March 31, 2006</td>
    </tr>
    <tr>
      <td>We are currently     engaged in an <font color="blue">active search</font> to fill these vacancies</td>
    </tr>
    <tr>
      <td>Our failure to fill     these <font color="blue">positions with qualified individuals could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>13       _________________________________________________________________                                     PDI, INC                     Annual Report on Form 10-K (Continued)       Our business may suffer if we fail to attract and retain <font color="blue">qualified sales</font>     <font color="blue"><font color="blue">representative</font>s</font></td>
    </tr>
    <tr>
      <td>The success and growth of our business <font color="blue">depends on</font> our ability to attract and     retain qualified <font color="blue">pharmaceutical</font> sales <font color="blue"><font color="blue">representative</font>s</font></td>
    </tr>
    <tr>
      <td>There is intense     <font color="blue">competition</font>  for  <font color="blue">pharmaceutical</font>  sales  <font color="blue"><font color="blue">representative</font>s</font> from CSOs and     <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>On occasion, our clients have hired the sales     <font color="blue"><font color="blue">representative</font>s</font> that we trained to detail their products</td>
    </tr>
    <tr>
      <td>We cannot be     certain that we can continue to attract and retain <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>If     we <font color="blue">cannot attract</font> and retain <font color="blue">qualified sales</font> personnel, we will not be able     to expand our teams business and our ability to perform under our existing     <font color="blue">contracts will</font> be impaired</td>
    </tr>
    <tr>
      <td>Our <font color="blue">controlling stockholder continues</font> to have <font color="blue">effective</font> control of us, which     <font color="blue">could delay</font> or prevent a change in <font color="blue">corporate control</font> that <font color="blue">may otherwise</font> be     <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>John P Dugan, our chairman, <font color="blue">beneficial</font>ly owns <font color="blue">approximately</font> 35prca of our     outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Dugan will be able to exercise     substantial  <font color="blue">control over</font> the election of all of our <font color="blue">directors</font>, and to     determine  the outcome of <font color="blue">most corporate actions</font> requiring stockholder     approval, including a <font color="blue">merger with</font> or into another company, the sale of all     or <font color="blue">substantially</font> all of our assets and <font color="blue">amendments</font> to our <font color="blue">certificate</font> of     <font color="blue">incorporation</font></td>
    </tr>
    <tr>
      <td>We have anti-takeover defenses that <font color="blue">could delay</font> or prevent an <font color="blue">acquisition</font>     and could <font color="blue">adversely</font> affect the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws include provisions, such as     providing for <font color="blue">three classes</font> of <font color="blue">directors</font>, which are intended to enhance the     likelihood of <font color="blue">continuity</font> and stability in the <font color="blue">composition</font> of our board of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These  <font color="blue">provisions may</font> make it more <font color="blue">difficult</font> to remove our     <font color="blue">directors</font> and <font color="blue">management</font> and may <font color="blue">adversely</font> affect the price of our common     stock</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">certificate</font> of <font color="blue">incorporation</font> authorizes the issuance     of  &amp;quote blank check &amp;quote  <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">provision could</font> have the effect of     delaying, deterring or preventing a <font color="blue">future takeover</font> or a change in control,     unless  the  takeover or change in control is <font color="blue">approved by</font> our board of     <font color="blue">directors</font>, even though the <font color="blue">transaction might offer</font> our <font color="blue">stockholders</font> an     <font color="blue">opportunity</font> to sell their shares at a price above the <font color="blue">current market price</font></td>
    </tr>
  </tbody>
</table>